COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models
L Xu, J Stevens, MB Hilton, S Seaman… - Science translational …, 2014 - science.org
Science translational medicine, 2014•science.org
Antiangiogenic agents that block vascular endothelial growth factor (VEGF) signaling are
important components of current cancer treatment modalities but are limited by alternative ill-
defined angiogenesis mechanisms that allow persistent tumor vascularization in the face of
continued VEGF pathway blockade. We identified prostaglandin E2 (PGE2) as a soluble
tumor-derived angiogenic factor associated with VEGF-independent angiogenesis. PGE2
production in preclinical breast and colon cancer models was tightly controlled by …
important components of current cancer treatment modalities but are limited by alternative ill-
defined angiogenesis mechanisms that allow persistent tumor vascularization in the face of
continued VEGF pathway blockade. We identified prostaglandin E2 (PGE2) as a soluble
tumor-derived angiogenic factor associated with VEGF-independent angiogenesis. PGE2
production in preclinical breast and colon cancer models was tightly controlled by …
Antiangiogenic agents that block vascular endothelial growth factor (VEGF) signaling are important components of current cancer treatment modalities but are limited by alternative ill-defined angiogenesis mechanisms that allow persistent tumor vascularization in the face of continued VEGF pathway blockade. We identified prostaglandin E2 (PGE2) as a soluble tumor-derived angiogenic factor associated with VEGF-independent angiogenesis. PGE2 production in preclinical breast and colon cancer models was tightly controlled by cyclooxygenase-2 (COX-2) expression, and COX-2 inhibition augmented VEGF pathway blockade to suppress angiogenesis and tumor growth, prevent metastasis, and increase overall survival. These results demonstrate the importance of the COX-2/PGE2 pathway in mediating resistance to VEGF pathway blockade and could aid in the rapid development of more efficacious anticancer therapies.
AAAS